Skip to main content

Table 2 Correlation of LINC00961 expression with clinicopathological features in BC patients

From: Evaluation of the potential role of long non-coding RNA LINC00961 in luminal breast cancer: a case–control and systems biology study

Characteristics No. of cases LINC00961 expression p-value
Low (N = 40) High (N = 39)
Age at diagnose
 ≤ 40 20 11 (28.9%) 9 (24.3%) 0.651
 > 40 55 27 (71.1%) 28 (75.7%)
Tumor size (cm)
 < 2 21 7 (18.9%) 14 (35.9%) 0.248
 2–5 41 22 (59.5%) 19 (48.7%)
 > 5 14 8 (21.6%) 6 (15.4%)
Group
 Luminal A 65 33 (82.5%) 32 (82.1%) 0.958
 Luminal B 14 7 (17.5%) 7 (17.9%)
Grade
 1 10 5 (12.5%) 5 (12.8%) 0.997
 2 55 28 (70.0%) 27 (69.2%)
 3 14 7 (17.5%) 7 (17.9%)
Stage
 I 6 2 (5.3%) 4 (11.4%) 0.466
 II 38 22 (57.9%) 16 (45.7%)
 III 29 14 (36.8%) 15 (42.9%)
Pathology of tumors*
 DCIS 1 1 (4.3%) 0 (0.0%) 0.415
 IDC 38 21 (91.3%) 17 (94.4%)
 ILC 1 0 (0.0%) 1 (5.6%)
 Others 1 1 (4.3%) 0 (0.0%)
Progesterone receptor
 Negative 10 4 (10.0%) 6 (15.4%) 0.472
 Positive 69 36 (90.0%) 33 (84.6%)
Estrogen receptor
 Negative 0 0 (0.0%) 0 (0.0%)
 Positive 79 40 (100.0%) 39 (100.0%)
HER2
 Negative 70 35 (87.5%) 35 (89.7%) 0.754
 Positive 9 5 (12.5%) 4 (10.3%)
Smoking
 No 41 18 (81.8%) 23 (95.8%) 0.012*
 Yes 5 4 (18.2%) 1 (4.2%)
  1. Fisher exact test was used for calculating p-value
  2. *p < 0.05